Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
October 30 2007 - 4:05PM
PR Newswire (US)
SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced that Adrian
Adams has been elected to the company's Board of Directors
effective immediately. "We are very pleased to welcome Adrian to
the Amylin Board," said Daniel M. Bradbury, President and CEO of
Amylin Pharmaceuticals. "His international experience as a highly
innovative, strategic business leader, combined with a track record
of building organizations and delivering optimum results will
enhance our Board's depth of experience." Mr. Adams currently
serves as President and CEO of Sepracor, Inc. Prior to this he was
President and Chief Executive Officer of Kos Pharmaceuticals from
2002 until the acquisition of the company by Abbott Laboratories in
December 2006. Mr. Adams has over 30 years of experience in both
specialty and large pharmaceutical organizations that, in addition
to Sepracor and Kos, included careers with ICI, SmithKline Beecham
and Novartis, and involved work and product launches in most
therapeutic areas. Mr. Adams has a broad background encompassing
research and development, sales, international and national product
marketing, business development and extensive general management
experience. He is a graduate of Manchester University in the United
Kingdom with a Bachelor of Science degree. In addition to serving
on the Amylin Board, Mr. Adams is actively involved as a board
member of PhRMA (Pharmaceutical Research and Manufacturer of
America). About Amylin Amylin Pharmaceuticals, Inc. is a
biopharmaceutical company committed to improving lives through the
discovery, development and commercialization of innovative
medicines. Amylin has developed and gained approval for two first-
in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research
and development activities leverage the company's expertise in
metabolism to develop potential therapies to treat diabetes and
obesity. Amylin is headquartered in San Diego, California with over
1,800 employees nationwide. Further information on Amylin
Pharmaceuticals is available at http://www.amylin.com/. DATASOURCE:
Amylin Pharmaceuticals, Inc. CONTACT: Alice Bahner Izzo, Executive
Director, Corporate Affairs of Amylin Pharmaceuticals, Inc.,
+1-858-552-2200 Web site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024